Table 1 Demographic and clinical characteristics of HIV/AIDS patients with antiepileptic drug (AED) exposure.
From: Clinical outcomes and immune benefits of anti-epileptic drug therapy in HIV/AIDS
| Â | Viremic | Aviremic | pvalue |
|---|---|---|---|
N | 114 | 55 | Â |
Median age (IQ range) | 46.2 (40.0-52.0) | 49.2 (42.1-56.2) | NS |
Median age at HIV diagnosis (IQ range) | 33.8 (27.0-41.95) | 36.0 (27.4-44.9) | NS |
Male gender | 84 (73.7%) | 44 (80.0%) | NS |
Ethnicity | Â | Â | NS |
   Caucasian | 90 (78.9%) | 43 (78.2%) |  |
   Aboriginal/Inuit/Metis | 7 (6.1%) | 3 (5.5%) |  |
   Black | 7 (6.1%) | 3 (5.5%) |  |
   Others | 10 (8.9%) | 6 (10.9%) |  |
HIV risk factor | Â | Â | NS |
   Homosexual/Bisexual | 51 (44.7%) | 26 (47.3%) |  |
   IVDU | 36 (31.6%) | 13 (23.6%) |  |
   Others | 27 (23.7%) | 16 (29.1%) |  |
HCV | 39 (34.2%) | 12 (21.8%) | NS |
Median duration of HIV infection (years) (IQ range) | 11.7 (7.5-16.6) | 12.6 (8.9-16.7) | NS |
Median baseline CD4+ T cell (cells/mm3) (IQ range) | 371 (185-583) | 241 (104-457) | <0.05 |
Median nadir CD4+ T cell (cells/mm3) (IQ range) | 120 (26-196) | 125 (32-222) | NS |
Median baseline CD8+ T cell (cells/mm3) (IQ range) | 784 (557-1134) | 726 (515-1120) | NS |
Median baseline log10 viral load (copies/ml) (IQ range) | 4.5 (3.5-5.1) | 4.3 (3.3-5.0) | NS |
Late presenter (%) | 34 (29.8%) | 22 (40.0%) | NS |
AIDS-defining illness | 50 (43.9%) | 24 (43.6%) | NS |
Mortality (%) | 23 (20.2%) | 8 (14.5%) | NS |